Jens Wuerthner is a physician scientist and currently holds the position of Head of Clinical Development – EU for ADC Therapeutics in Lausanne, Switzerland. He is a licensed physician in Germany, Switzerland and the UK and a fellow of the Faculty of Pharmaceutical Medicine, UK.
Dr. Wuerthner qualified as a physician in Hamburg, Germany, and subsequently worked in clinical oncology at the University of Freiburg and in cancer research at the National Institutes of Health, Bethesda, USA. He continued preclinical cancer research upon his return to Germany, further characterizing a family of proteins in the signal transduction cascade of TGF-beta, including generation of knock out mice. This work lead to a transition to the R&D department of AstraZeneca Oncology in Alderley Park, UK. Subsequently, he took up more senior roles in the GSK Biopharm R&D unit in Stevenage, UK, and Novartis Translational Oncology in Basel, Switzerland. He gained pharmaceutical development experience ranging from pre-CS to clinical POC and registration, predominantly in oncology, but also in infection and immunology. His main research interest lies in translational oncology.
In addition to his work in industry, Dr. Wuerthner has been an honorary lecturer of the University of Manchester and currently serves as a visiting professor for Kings College, Faculty of Life Sciences & Medicine – Institute of Pharmaceutical Science, and as a member of the board of examiners of the Faculty of Pharmaceutical Medicine.
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Joan Shutt
+44 (0)207 092 1134
joan.shutt@terrapinn.com